|
| ORIGINAL ARTICLE |
 |
|
|
| Year : 2021 |
Volume
: 32 | Issue : 6 | Page
: 1628-1636 |
|
Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease
Areej Adel Sheerah1, Rafif Ali Al-Ahmed1, Sherif M. El-Desoky2, Khalid Abdulaziz Alhasan3, Amr S. Albanna4, Mohamed A. Shalaby2, Jameela Abdulaziz Kari2
1 Department of Pediatrics, Pediatric Nephrology Unit, King Abdulaziz University Hospital, Jeddah, Saudi Arabia
2 Department of Pediatrics, Pediatric Nephrology Unit; Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
3 Department of Pediatrics, College of Medicine, King Saud University; Division of Pediatric Kidney Transplant, Organ Transplant Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
4 King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
Correspondence Address:
Areej Adel Sheerah
Department of Pediatrics, Pediatric Nephrology Unit, King Abdulaziz University, P. O. Box 80215, Jeddah 21589, Saudi Arabia.
Saudi Arabia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1319-2442.352423
|
|
|
Advanced chronic kidney disease with mineral and bone disorder have a significant obstacles to control serum bone profile [serum intact parathyroid hormone (iPTH), calcium and phosphorus] which subsequently have major effect on optimal bone strength, final adult height, and cardiovascular health. A retrospective, observational study, including a total of 36 children with end-stage kidney disease (ESKD). Fourteen children who were prescribed cinacalcet had been compared with the remaining 22 children who were managed with standard care. We report the efficacy and safety of cinacalcet for treatment of refractory secondary hyperparathyroidism (SHPT) in children with ESKD. After 6 months of cinacalcet treatment, the mean level of iPTH serum level decreased by 56% from 202 pmol/L [95% confidence interval (CI): 150-253] to 88 pmol/L (95% CI: 41-136), compared to the change observed in the control group (P <0.001). None of our patients reported serious adverse effects or developed hypocalcemia. Cinacalcet could be an effective and safe alternative to treat severe SHPT in children with ESKD. Further long-term and large-scale studies are necessary to confirm its safety and efficacy.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
|
|
